Home > Healthcare > Pharmaceuticals > Clinical Nutrition > Clinical Nutrition Market
Clinical Nutrition Market size was valued at over USD 50.5 billion in 2022. Driven by the growing occurrence of metabolic disorders and numerous other chronic conditions worldwide, the market is expected to grow at over 10% CAGR from 2023 to 2032.
<>
Surging prevalence of chronic conditions such as respiratory diseases, cardiovascular ailments, cancer, gastrointestinal disorders, and malnourishment among adults and children is elevating the need for nutritional support. Oropharyngeal dysphagia, while commonly observed among the geriatric population, is often also reported in patients suffering from neurological diseases such as multiple sclerosis, oropharyngeal dysphagia, Parkinson's disease, and dementia.
The swallowing problems caused by the condition are creating a strong impetus for clinical nutrition, especially as the disease load of neurological disorders continues to rise across the globe. As per a report published by WHO in 2022, the number of people suffering from dementia is likely to reach 78 million in 2030 and 139 million in 2050.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Clinical Nutrition Market Size in 2022: | USD 50.5 billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 10% |
2032 Value Projection: | USD 128 billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 330 |
Tables, Charts & Figures: | 679 |
Segments covered: | Product, Consumer, Application, Distribution Channel, and Dosage Formulation |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Strict regulations governing the clinical nutrition landscape may hold back the industry scenario through 2032. In the US, the FDA regulates clinical nutrition products under a different set of guidelines than those covering drug products and conventional food items. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the FDA prohibits the sale of clinical nutrition products that are misbranded of adulterated in any way.
With patient lives on the line, manufacturers have to strictly adhere to the regulatory guidelines, and any type of alterations to the product compositions have to get approved by the governing body before commercialization can be commenced. This makes the cost of entry particularly high for newcomers in the sector.